Clinical Trial Update: Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating TNX-601 ER as monotherapy versus placebo in adults with major depressive disorder has completed, with results posted on 2025-02-17.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• TNX-601 ER

Snippet

Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: Depression, Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-02-17